Рациональная фармакотерапия в кардиологии (Sep 2015)

THE ROLE OF P-GLYCOPROTEIN IN RATIONAL PHARMACOTHERAPY IN CARDIOLOGY

  • A. V. Shulkin,
  • E. N. Yakusheva,
  • N. M. Popova

DOI
https://doi.org/10.20996/1819-6446-2013-9-6-701-707
Journal volume & issue
Vol. 9, no. 6
pp. 701 – 707

Abstract

Read online

On the basis of the analysis of published data the role of P-glycoprotein, carrier protein, in rational pharmacotherapy in cardiology was shown on the example of its substrates – digoxin, antiplatelet agents and anticoagulants. Determination of C3435T polymorphism of multidrug resistance gene (MDR1), encoding P-glycoprotein, in pharmacotherapy with digoxin, antiplatelet drugs (clopidogrel tikagrelol, prasugrel) and anticoagulants (dabigatran etexilate, rivaroxaban, edoxaban) is not feasible in routine practice. Drug in- teractions have clinical implications for the efficacy and safety of pharmacotherapy in coadministration of these drugs with P-glycoprotein substrates, inducers and inhibitors.

Keywords